Initiating Azathioprine for Crohn's Disease

Barrett G. Levesque, Edward Vincent Loftus, Jr

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Azathioprine (AZA) and 6-mercaptopurine are therapeutic options for patients with moderate to severe inflammatory Crohn's disease. AZA has both a complex metabolism and potential for adverse events that can be clinically challenging. AZA has been shown to maintain remission and reduce corticosteroid use in patients with Crohn's disease. There is heterogeneous thiopurine methyltransferase metabolism among patients, which has implications for clinical dosing and risk for adverse events. Routine thiopurine methyltransferase testing before the initiation of AZA will reduce early leukopenia and is mandatory to avoid potentially life-threatening myelotoxicity. Thiopurine metabolite assays may aid in the assessment of adherence and adverse events. Patients who do not respond to AZA therapy may benefit from the addition of biologic therapy or methotrexate.

Original languageEnglish (US)
Pages (from-to)460-465
Number of pages6
JournalClinical Gastroenterology and Hepatology
Volume10
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Azathioprine
Crohn Disease
thiopurine methyltransferase
6-Mercaptopurine
Biological Therapy
Leukopenia
Methotrexate
Adrenal Cortex Hormones
Therapeutics

Keywords

  • 6-Mercaptopurine
  • 6-Methylmercaptopurine
  • 6-Thioguanine
  • Azathioprine
  • Crohn's Disease
  • Thiopurine Methyltransferase

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Initiating Azathioprine for Crohn's Disease. / Levesque, Barrett G.; Loftus, Jr, Edward Vincent.

In: Clinical Gastroenterology and Hepatology, Vol. 10, No. 5, 05.2012, p. 460-465.

Research output: Contribution to journalArticle

@article{f6b9128dc73e4f8b88427d9795c2fb3e,
title = "Initiating Azathioprine for Crohn's Disease",
abstract = "Azathioprine (AZA) and 6-mercaptopurine are therapeutic options for patients with moderate to severe inflammatory Crohn's disease. AZA has both a complex metabolism and potential for adverse events that can be clinically challenging. AZA has been shown to maintain remission and reduce corticosteroid use in patients with Crohn's disease. There is heterogeneous thiopurine methyltransferase metabolism among patients, which has implications for clinical dosing and risk for adverse events. Routine thiopurine methyltransferase testing before the initiation of AZA will reduce early leukopenia and is mandatory to avoid potentially life-threatening myelotoxicity. Thiopurine metabolite assays may aid in the assessment of adherence and adverse events. Patients who do not respond to AZA therapy may benefit from the addition of biologic therapy or methotrexate.",
keywords = "6-Mercaptopurine, 6-Methylmercaptopurine, 6-Thioguanine, Azathioprine, Crohn's Disease, Thiopurine Methyltransferase",
author = "Levesque, {Barrett G.} and {Loftus, Jr}, {Edward Vincent}",
year = "2012",
month = "5",
doi = "10.1016/j.cgh.2012.01.018",
language = "English (US)",
volume = "10",
pages = "460--465",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Initiating Azathioprine for Crohn's Disease

AU - Levesque, Barrett G.

AU - Loftus, Jr, Edward Vincent

PY - 2012/5

Y1 - 2012/5

N2 - Azathioprine (AZA) and 6-mercaptopurine are therapeutic options for patients with moderate to severe inflammatory Crohn's disease. AZA has both a complex metabolism and potential for adverse events that can be clinically challenging. AZA has been shown to maintain remission and reduce corticosteroid use in patients with Crohn's disease. There is heterogeneous thiopurine methyltransferase metabolism among patients, which has implications for clinical dosing and risk for adverse events. Routine thiopurine methyltransferase testing before the initiation of AZA will reduce early leukopenia and is mandatory to avoid potentially life-threatening myelotoxicity. Thiopurine metabolite assays may aid in the assessment of adherence and adverse events. Patients who do not respond to AZA therapy may benefit from the addition of biologic therapy or methotrexate.

AB - Azathioprine (AZA) and 6-mercaptopurine are therapeutic options for patients with moderate to severe inflammatory Crohn's disease. AZA has both a complex metabolism and potential for adverse events that can be clinically challenging. AZA has been shown to maintain remission and reduce corticosteroid use in patients with Crohn's disease. There is heterogeneous thiopurine methyltransferase metabolism among patients, which has implications for clinical dosing and risk for adverse events. Routine thiopurine methyltransferase testing before the initiation of AZA will reduce early leukopenia and is mandatory to avoid potentially life-threatening myelotoxicity. Thiopurine metabolite assays may aid in the assessment of adherence and adverse events. Patients who do not respond to AZA therapy may benefit from the addition of biologic therapy or methotrexate.

KW - 6-Mercaptopurine

KW - 6-Methylmercaptopurine

KW - 6-Thioguanine

KW - Azathioprine

KW - Crohn's Disease

KW - Thiopurine Methyltransferase

UR - http://www.scopus.com/inward/record.url?scp=84859870647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859870647&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2012.01.018

DO - 10.1016/j.cgh.2012.01.018

M3 - Article

C2 - 22330233

AN - SCOPUS:84859870647

VL - 10

SP - 460

EP - 465

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 5

ER -